Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice

Executive Summary

Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends the "bully pulpit" approach to get industry's attention. A panel of former chief counsels stressed that the agency cannot continue to ignore First Amendment free speech issues.


Related Content

2018 Slow For Advertising Enforcement – But Don’t Get Complacent
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information
Xtampza ER Warnings Can't Be Hidden Behind Table And Chairs, US FDA Tells Collegium
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
Off-Label Promotion Settlement Includes Optional Preclearance Process
FDA Outlines Next Steps For Online Repository And Standard Elements For Device Labeling


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts